Aripiprazole, sold under the brand names Abilify and Aristada among others, is an atypical antipsychotic.
FactSnippet No. 626,612 |
Aripiprazole, sold under the brand names Abilify and Aristada among others, is an atypical antipsychotic.
FactSnippet No. 626,612 |
Aripiprazole is primarily used for the treatment of schizophrenia or bipolar disorder.
FactSnippet No. 626,614 |
Aripiprazole is effective for the treatment of acute manic episodes of bipolar disorder in adults, children, and adolescents.
FactSnippet No. 626,615 |
Aripiprazole is an effective add-on treatment for major depressive disorder; however, there is a greater rate of side effects such as weight gain and movement disorders.
FactSnippet No. 626,616 |
Aripiprazole is not currently approved for the treatment of OCD and is instead used off-label for this indication.
FactSnippet No. 626,617 |
Aripiprazole has been reported to provide some benefit in improving cognitive functioning in people with ADHD without other psychiatric comorbidities, though the results have been disputed.
FactSnippet No. 626,618 |
Aripiprazole was discovered in 1988 by scientists at the Japanese firm Otsuka Pharmaceutical.
FactSnippet No. 626,619 |
Aripiprazole is a partial agonist of the serotonin 5-HT1A receptor.
FactSnippet No. 626,620 |
Aripiprazole was frequently found to be a partial agonist, with an intrinsic activity that could be low, intermediate, or high.
FactSnippet No. 626,621 |
Aripiprazole has a favorable pharmacological profile in being a 5-HT2A antagonist and a 5-HT2C partial agonist.
FactSnippet No. 626,622 |
Aripiprazole is a phenylpiperazine and is chemically related to nefazodone, etoperidone, and trazodone.
FactSnippet No. 626,623 |
Aripiprazole was discovered by scientists at Otsuka Pharmaceutical and was called OPC-14597.
FactSnippet No. 626,624 |
Aripiprazole has been approved by the FDA for the treatment of both acute manic and mixed episodes, in people older than ten years.
FactSnippet No. 626,625 |
Aripiprazole has been described as the prototypical third-generation antipsychotic, as opposed to first-generation antipsychotics like haloperidol and second-generation antipsychotics like clozapine.
FactSnippet No. 626,626 |
Aripiprazole was under development for the treatment of attention-deficit hyperactivity disorder, but development for this indication was discontinued.
FactSnippet No. 626,627 |
Aripiprazole has been studied for the treatment of amphetamine dependence and other substance use disorders, but more research is needed to support aripiprazole for these potential uses.
FactSnippet No. 626,628 |
Aripiprazole is under development for the treatment of agitation and pervasive child development disorders.
FactSnippet No. 626,629 |